Industry
Nature Reviews Drug Discovery
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry
Nature Reviews Drug Discovery
Industry N Nature Medicine
Manufacturing N Nature Reviews Bioengineering
Industry N Nature Reviews Bioengineering
Industry
MedCity News
While the immune reset field is mainly focused on depleting pathogenic B cells, ai3Bio is applying its novel approach to inflammatory T cells. The startup’s initial disease targets are autoimmune disorders of the liver that have few treatment options if any at all. The post Immun…
Manufacturing P pharmaphorum
Bayer pledges $2.2bn to US manufacturing facility Phil.Taylor Sun, 04/10/2026 - 18:57
Clinical P Pharmafile
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two phase 3 trials, cutting exacerbation rates by 29% and 34% among former smokers. Its OBERON and TITANIA trials were replicate, double-blind, plac…
Industry P Pharmafile
Brenntag Pharma and dsm-firmenich have entered a long-term global distribution partnership covering GMP-grade vitamins for biopharmaceutical manufacturing. Under the agreement, Brenntag will have exclusive distribution rights across North America, Latin America, Europe, the Middl…
Software T The Niche
It’s been a wild few weeks for AI in science with the latest revelation that a key UK funder did AI grant review. Let’s start there with our weekly discussion. I should note that 13 years ago I drew a cartoon imagining something like this with robots reviewing grants. Mice with h…
Industry
BioCentury
BIOCENTURY | DEALSNOVARTIS TURNS TO MRNA-ENCODED ENGAGERS FOR B CELL DEPLETIONPharma pays $575M up front for Abogen’s CD3 x CD19 engager to treat autoimmune diseases
Industry
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTCIRCLE’S $92.5M ROUND PUTS CYCLIN D1 PROGRAM AHEAD OF CLINICAL LEADPreclinical combination data drive CID-165’s priority over CID-078, with deeper breast cancer responses the goal
Industry
BioCentury
BIOCENTURY | EDITOR'S COMMENTARYSMALL GLOBE, BIG PRECEDENT: A PERSPECTIVEThe mandatory Medicare Part B MFN model has shrunk, laying bare the real issues
Industry
BioCentury
BIOCENTURY | DATA BYTEPHARMA PARTNERING IN CHINA GETS EARLIER AND BROADERMerck, Novo and Novartis pay ≥$300M apiece for early assets as China partnering expands beyond cancer antibodies
Industry B BioPharm International
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
Industry
GEN
A long-duration single-molecule imaging platform from the Broad Institute and MIT has revealed unexpected stability in homodimers of HER3, one of the most enigmatic members of the ErbB receptor family. The post Watching Cancer Proteins in Real Time, with Help from Rare Earth Elem…
Industry
BioCentury
BIOCENTURY | FINANCEHATTERAS BANKS ON PORTFOLIO WITH UPSIZED OPPORTUNITY FUNDFirm sets $100M target for vehicle designed for further investment in private portfolio companies, even amid improved environment for exits
Funding
BioCentury
BIOCENTURY | FINANCETRIO OF BIOTECHS DRAW NINE-FIGURE FUNDINGS: PUBLIC EQUITY REPORTImmix, Sagimet, and Pyxis all receive funding; plus AstraZeneca/Summit
Industry
Fierce Biotech
Accelerating Oligonucleotide Therapeutics Oligonucleotide therapeutics represent a paradigm shift in precision medicine, targeting RNA to modulate gene expression with unmatched specificity for genetic and rare diseases. This eBook explores Evotec's oligonucleotide journey and cu…
Industry P Pharmaceutical Executive
Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral…
Industry
GEN
Working with mice, scientists have for the first time identified a set of neurons in the brain that play a role in generating anxiety after exposure to cannabinoid drugs, especially under stressful conditions. The post Neurons Involved in Generating Anxiety After Cannabinoid Drug…
Industry
Inside Precision Medicine
A new molecular diagnostic platform could help laboratories identify bacterial infections and key antimicrobial resistance genes more quickly and without specialized equipment. The post CRISPR-Based Test Offers Fast Antimicrobial Resistance Detection in Low-Resource Settings appe…
Industry
Inside Precision Medicine
A urine cell-free RNA test detected localized bladder cancer with high sensitivity and may also reveal residual disease and help predict response to BCG immunotherapy versus chemotherapy. The post Urine RNA Test Could Detect Bladder Cancer and Predict Treatment Response appeared…
Industry
Inside Precision Medicine
A blood-based epigenomic approach captured molecular features of small-cell lung cancer that are normally measured in tumor tissue. The method could eventually help clinicians monitor tumor state and subtype as disease evolves. The post Plasma Epigenomic Profiling May Enable Noni…
Regulatory
GEN
FDA Chief Scientist Steven Kozlowski, MD, said the updated FARS would come out early in FY 2027 but offered no further specifics on timing. The post FDA to Highlight Aging, Longevity Medicine in Planned FARS Update appeared first on GEN - Genetic Engineering and Biotechnology New…
Agriculture
CropLife
Eric Sfiligoj and Amy Asmus explore diesel spikes, fuel tax holidays, ag retailer business shifts, and rising future value. The post CropLife Retail Week: Diesel Shock, Wet Grain Costs, and the Shifting Ag Retail Value Proposition appeared first on CropLife.
Regulatory
MedCity News
Pfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during European Academy of Dermatology and Venereology annual meeting. If Pfizer’s daily pill is approved, it would compete against an Incyte topical crea…
Manufacturing
Fierce Biotech
How to Choose a Biologics CDMO: 4 Criteria That Matter the Most scox Fri, 10/02/2026 - 13:28
Industry
Fierce Pharma
Evaluating Combinatorial Targets for Precision Therapeutics: A Pathologist’s View scox Fri, 10/02/2026 - 13:10 Wed, 11/18/2026 - 12:00 Resource Type Webinar William Mifsud, PhD Tad George, PhD Promotion End Thu, 04/08/2027 - 13:14 Precision therapeutic strategies that target mult…
Clinical A Applied Clinical Trials
Hierarchical composite endpoints analyzed through pairwise comparisons more accurately reflect multifaceted treatment benefit than time-to-first-event composites, but transparent outcome prioritization, patient involvement in ranking, and reporting of Net Treatment Benefit remain…
Industry B BioPharm International
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Agriculture
Global Ag Tech Initiative
Discover how high-resolution satellite analytics can support crop scouting, variable-rate management, crop insurance investigations, and more. The post Tech Talk: Satshot on AI-Enhanced Satellite Imagery appeared first on Global Ag Tech Initiative.
Industry
Pharmaceutical Processing World
ISO 9001, ISO 14001 and ISO 45001 are all being revised, which leaves quality (QMS), environmental (EMS) and occupational health and safety (OH&S) managers, along with top management, with required work ahead to meet the new requirements. Because the revisions put more weight…
Industry
European Biotechnology
Novartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an experimental treatment that uses mRNA to make a B-cell-depleting drug inside the patient’s body. The post Novartis bets up to $7.8B on Abogen’s mRNA autoimmune thera…
Industry B BioPharm International
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid art…
Regulatory
MedTech Dive
The device could help young patients avoid multiple open-heart surgeries as they grow, FDA officials said.
Clinical
Clinical Trials Arena
Trial operators are increasingly incorporating imaging tools and related artificial intelligence (AI)-based tools into their study protocols. The post Brainomix’s e-Lung shows progression and treatment response in Phase III trial appeared first on Clinical Trials Arena.
Industry B BioPharm International
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on…
Agriculture E European Seed
Euroseeds is urging EU policymakers to keep organic breeding rules focused on variety performance, warning that additional breeding-process requirements could raise costs, reduce genetic access and limit farmers’ variety choice. The post Euroseeds Urges Focus on Variety Performan…
Agriculture
AgriBusiness Global
In AgriBusiness Global Report, José Borgo, newly appointed Chief Commercial Officer of Rovensa Next, discusses how agribusinesses can drive sustainable growth through strategic acquisitions and why true scale goes far beyond top-line revenue. The post AgriBusiness Global Report:…
Regulatory
MedTech Dive
The FDA outlined its A-list and B-list guidance priorities for the 2027 fiscal year.